Analyzing Arcutis Biotherapeutics (NASDAQ:ARQT) & TetraLogic Pharmaceuticals (OTCMKTS:TLOG)

Arcutis Biotherapeutics (NASDAQ:ARQT) and TetraLogic Pharmaceuticals (OTCMKTS:TLOG) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Institutional & Insider Ownership

0.0% of TetraLogic Pharmaceuticals shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 15.4% of TetraLogic Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Arcutis Biotherapeutics and TetraLogic Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07 million	8.09	-$16.14 million	($0.14)	-175.21
TetraLogic Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

TetraLogic Pharmaceuticals has lower revenue, but higher earnings than Arcutis Biotherapeutics.

Risk and Volatility

Arcutis Biotherapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, TetraLogic Pharmaceuticals has a beta of 5.01, meaning that its share price is 401% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Arcutis Biotherapeutics and TetraLogic Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1	2	5	0	2.50
TetraLogic Pharmaceuticals	0	0	0	0	0.00

Arcutis Biotherapeutics presently has a consensus target price of $34.00, indicating a potential upside of 38.61%. Given Arcutis Biotherapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Arcutis Biotherapeutics is more favorable than TetraLogic Pharmaceuticals.

Profitability

This table compares Arcutis Biotherapeutics and TetraLogic Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-4.29%	-10.26%	-4.30%
TetraLogic Pharmaceuticals	N/A	N/A	N/A

Summary

TetraLogic Pharmaceuticals beats Arcutis Biotherapeutics on 6 of the 10 factors compared between the two stocks.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

About TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.